Nuclivision has raised a €5M seed round
April 24, 2025
We’re proud to announce the closing of our €5M seed round with HERAN Partners, LUMO Labs, and imec.istart future fund. Their trust, expertise, and capital will enable us to accelerate the commercialization of our PET image enhancement software, Nuclarity, across Europe and the US. This milestone also strengthens our commitment to continued innovation in the promising & growing field of nuclear medicine—driven by rising oncology volumes, radiotracer innovations, and the rise of theranostics. As one of the few software-first players, we’re uniquely positioned to make nuclear medicine safer, more affordable, and more accessible.
Nuclivision raises 5 million euros in an investment round co-led by LUMO Labs and Heran Partners, for AI breakthrough in faster and safer detection of cancer and Alzheimer's
PRESS RELEASE - GHENT, BELGIUM – April 24, 2025
Ghent-basedmedtech startup Nuclivision has raised €5 million from renowned investors, including LUMO Labs, Heran Partners, and the imec.istart future fund, for the commercial rollout of their AI software platform Nuclarity that enables faster, safer, and more affordable medical imaging through PET scans.
PET (positron emission tomography) is a powerful imaging technique that makes it possible to visualize physiological processes, such as the energy consumption of cells, and abnormalities thereof. However, the radiotracers used come with costs and radiation risks, which currently limits accessibility.
Nuclivision's software makes it possible to perform scans with less radiation and in a shorter time, without compromising on image quality. This represents a breakthrough for the use of medical imaging in the early detection and treatment of cancer and Alzheimer's.
"Medical imaging is at an inflection point," says Nuclivision's CEO, Maarten Larmuseau. "With the rapid growth within radiopharma and theranostics, the use of AI and smart software is becoming necessary to handle the increased demand for PET and SPECT scans for conditions such as cancer and Alzheimer's."
With its groundbreaking software, Nuclivision aims to not only improve the quality of care but also address a crucial problem: PET scans are currently expensive and require the use of radioactive substances, which poses both financial and health challenges.
Geoffrey D’hondt from Heran Partners comments: "Nuclivision is uniquely positioned in the field of AI-driven image enhancement for PET scans with the Nuclarity platform. By reducing the amount of time and the amount of costly and harmful radiotracers required for accurate medical imaging, Nuclarity not only reduces the time pressure on nuclear medicine departments but also the cost and harmful environmental and health impact of PET scans."
The startup is currently in the final phase of regulatory approval for the software platform. As soon as this is completed, the strategic entry into the European market will follow and into the American market later this year.
"The completion of the regulatory approval process marks the beginning of a new growth phase for Nuclivision that is crucial for the actual deployment and impact of their technology," explains Sven Bakkes, Founding Partner at LUMO Labs. He continues: "We look forward to supporting the founders and the growing team of Nuclivision in this, of course with indispensable growth capital but also with expertise and frameworks in the field of business operations and impact and with opening up our network."
Kris Vandenberk, Managing Partner at imec.istart future fund adds: "We believe that Nuclivision can set a new standard in improving PET imaging. With seamless integration into hospital systems, the platform shows strong potential. We fully support the rollout of this platform."
This investment round follows previous investments in Nuclivision by imec.istart and Lumiares.
